journal contribution
posted on 2023-03-30, 23:43 authored by Orli Yogev, Karen Barker, Arti Sikka, Gilberto S. Almeida, Albert Hallsworth, Laura M. Smith, Yann Jamin, Ruth Ruddle, Alexander Koers, Hannah T. Webber, Florence I. Raynaud, Sergey Popov, Chris Jones, Kevin Petrie, Simon P. Robinson, Hector C. Keun, Louis Chesler Supplementary Figure 1. The p53 pathway is functional in Th-MYCN neuroblastomas. Supplementary Figure 2. Immunohistochemical analysis of Th-MYCN mice. Supplementary Figure 3. Restoration of p53 has no effect on tumor growth rate or penetration in Th-MYCN/Trp53KI/KI mice. Supplementary Figure 4. Th-MYCN/Trp53KI/KI pups display increased percentage of neoplastic islands compared to Th-MYCN/Trp53WT/WT pups. Supplementary Figure 5. Figure S5 Th-MYCN/Trp53WT/WT and Th-MYCN/Trp53KI/K tumors are similar in their basal DNA damage levels.
Funding
The Neuroblastoma Society
MRC funding
The Felix White Cancer Charity
Cancer Research UK and EPSRC to the Cancer Imaging Centre at the Institute of Cancer Research (ICR) and The Royal Marsden Hospital, in association with the MRC and Department of Health
The Wellcome Trust
EPSRC
NHS funding to the NIHR Biomedical Research Centre at The Royal Marsden and the ICR, and a Paul O'Gorman Post doctoral Fellowship funded by Children with Cancer UK
History
ARTICLE ABSTRACT
Neuroblastoma is the most common childhood extracranial solid tumor. In high-risk cases, many of which are characterized by amplification of MYCN, outcome remains poor. Mutations in the p53 (TP53) tumor suppressor are rare at diagnosis, but evidence suggests that p53 function is often impaired in relapsed, treatment-resistant disease. To address the role of p53 loss of function in the development and pathogenesis of high-risk neuroblastoma, we generated a MYCN-driven genetically engineered mouse model in which the tamoxifen-inducible p53ERTAM fusion protein was expressed from a knock-in allele (Th-MYCN/Trp53KI). We observed no significant differences in tumor-free survival between Th-MYCN mice heterozygous for Trp53KI (n = 188) and Th-MYCN mice with wild-type p53 (n = 101). Conversely, the survival of Th-MYCN/Trp53KI/KI mice lacking functional p53 (n = 60) was greatly reduced. We found that Th-MYCN/Trp53KI/KI tumors were resistant to ionizing radiation (IR), as expected. However, restoration of functional p53ERTAM reinstated sensitivity to IR in only 50% of Th-MYCN/Trp53KI/KI tumors, indicating the acquisition of additional resistance mechanisms. Gene expression and metabolic analyses indicated that the principal acquired mechanism of resistance to IR in the absence of functional p53 was metabolic adaptation in response to chronic oxidative stress. Tumors exhibited increased antioxidant metabolites and upregulation of glutathione S-transferase pathway genes, including Gstp1 and Gstz1, which are associated with poor outcome in human neuroblastoma. Accordingly, glutathione depletion by buthionine sulfoximine together with restoration of p53 activity resensitized tumors to IR. Our findings highlight the complex pathways operating in relapsed neuroblastomas and the need for combination therapies that target the diverse resistance mechanisms at play. Cancer Res; 76(10); 3025–35. ©2016 AACR.
